Sana Biotechnology Inc (SANA)
8.625
+0.08
(+0.88%)
USD |
NASDAQ |
May 20, 16:00
8.625
0.00 (0.00%)
After-Hours: 18:36
Sana Biotechnology Cash from Financing (Quarterly): 186.40M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 186.40M |
December 31, 2023 | 1.718M |
September 30, 2023 | 0.187M |
June 30, 2023 | 29.50M |
March 31, 2023 | 0.236M |
December 31, 2022 | 1.061M |
September 30, 2022 | 1.621M |
June 30, 2022 | 1.579M |
March 31, 2022 | 0.652M |
Date | Value |
---|---|
December 31, 2021 | 3.119M |
September 30, 2021 | 1.596M |
June 30, 2021 | 0.333M |
March 31, 2021 | 626.70M |
December 31, 2020 | 0.103M |
September 30, 2020 | 0.004M |
June 30, 2020 | 435.58M |
March 31, 2020 | 0.002M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.002M
Minimum
Mar 2020
626.70M
Maximum
Mar 2021
75.91M
Average
1.579M
Median
Jun 2022
Cash from Financing (Quarterly) Benchmarks
Rocket Pharmaceuticals Inc | 1.184M |
Solid Biosciences Inc | 107.24M |
Dyne Therapeutics Inc | 408.39M |
Taysha Gene Therapies Inc | -0.022M |
Tenaya Therapeutics Inc | 46.77M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -65.63M |
Cash from Investing (Quarterly) | -77.23M |
Free Cash Flow | -273.64M |
Free Cash Flow Per Share (Quarterly) | -0.375 |
Free Cash Flow Yield | -15.71% |